Edward Nash
Stock Analyst at Canaccord Genuity
(3.80)
# 783
Out of 5,182 analysts
79
Total ratings
50%
Success rate
10.06%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Initiates: Buy | $101 | $46.03 | +119.42% | 1 | Apr 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Buy | $47 → $56 | $41.16 | +36.05% | 11 | Apr 14, 2026 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $8 | $1.41 | +467.38% | 4 | Apr 6, 2026 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 → $5 | $0.88 | +470.26% | 3 | Apr 1, 2026 | |
| CORT Corcept Therapeutics | Maintains: Buy | $100 → $110 | $46.97 | +134.19% | 13 | Mar 26, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $89 → $130 | $86.10 | +51.00% | 2 | Mar 24, 2026 | |
| PLRX Pliant Therapeutics | Maintains: Hold | $4 → $3 | $1.22 | +145.90% | 3 | Mar 13, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Buy | $62 | $51.04 | +21.49% | 1 | Feb 19, 2026 | |
| VERU Veru Inc. | Initiates: Buy | $25 | $2.34 | +968.38% | 1 | Dec 18, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $522.11 | +12.43% | 12 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $107 | $33.61 | +218.36% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 | $8.56 | +227.10% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.14 | +289.11% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 | $34.06 | +82.03% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.20 | +431.25% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $4.20 | -52.38% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.62 | +28,936.94% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | - | - | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $25.02 | +227.74% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $18.05 | +165.93% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.38 | +11,981.78% | 1 | Nov 8, 2017 |
Structure Therapeutics
Apr 27, 2026
Initiates: Buy
Price Target: $101
Current: $46.03
Upside: +119.42%
Travere Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $47 → $56
Current: $41.16
Upside: +36.05%
Cardiol Therapeutics
Apr 6, 2026
Maintains: Buy
Price Target: $8
Current: $1.41
Upside: +467.38%
Rani Therapeutics Holdings
Apr 1, 2026
Maintains: Buy
Price Target: $9 → $5
Current: $0.88
Upside: +470.26%
Corcept Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $100 → $110
Current: $46.97
Upside: +134.19%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $89 → $130
Current: $86.10
Upside: +51.00%
Pliant Therapeutics
Mar 13, 2026
Maintains: Hold
Price Target: $4 → $3
Current: $1.22
Upside: +145.90%
Kiniksa Pharmaceuticals International,
Feb 19, 2026
Initiates: Buy
Price Target: $62
Current: $51.04
Upside: +21.49%
Veru Inc.
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.34
Upside: +968.38%
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $522.11
Upside: +12.43%
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $33.61
Upside: +218.36%
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $8.56
Upside: +227.10%
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $5.14
Upside: +289.11%
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $34.06
Upside: +82.03%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.20
Upside: +431.25%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $4.20
Upside: -52.38%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.62
Upside: +28,936.94%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: -
Upside: -
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $25.02
Upside: +227.74%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $18.05
Upside: +165.93%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.38
Upside: +11,981.78%